JDRF Blog

Latest in Glucose control

  • JDRF and Gore Invest in Development of Implantable Insulin Delivery System

    January 22, 2020

    PhysioLogic Devices, a JDRF-funded company that is dedicated to transforming the treatment of type 1 diabetes (T1D), wants to develop the ThinPump™—a...

  • FDA Grants Breakthrough Device Status: iLet Bionic Pancreas

    December 23, 2019

    Earlier this week, Beta Bionics announced that the Food and Drug Administration (FDA) has granted breakthrough device designation to the company’s iLet...

  • FDA Authorizes a Second Artificial Pancreas System

    December 13, 2019

    The Food and Drug Administration (FDA) today authorized an algorithm that enables the second artificial pancreas system: The Control-IQ™ advanced hybrid closed...

  • One Less Device: Combining CGM and Insulin Infusion—JDRF Clinical Trial

    December 9, 2019

    JDRF is funding work to build a better insulin infusion set; the current infusion sets can be uncomfortable and unreliable, and need...

  • JDRF Clinical Trial Results Announced at the 55th EASD Meeting

    September 18, 2019

    A protein, called glucokinase (or GK), acts as a key regulator of sugar levels in the body. If blood glucose levels are...

  • FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia

    September 11, 2019

    “The approval of the GVOKE HypoPenTM is an important step forward for people with diabetes. Severe hypoglycemia is a terrifying and dangerous...

  • FDA Approves the First Low Blood Sugar Treatment WITHOUT an Injection

    July 25, 2019

    Type 1 diabetes (T1D) can bring the fear of developing low blood sugar, called hypoglycemia, which can arise if someone takes too...

  • Proof-of-Concept for Hypoglycemia Prevention

    June 5, 2019

    Hypoglycemia, or low blood sugar, can have serious effects, and it is, for most people with type 1 diabetes (T1D), the most...